siRNA Delivery: From Lipids to Cell-penetrating Peptides and Their Mimics

Chemical Biology and Drug Design

Volumn 80, Issue 6, 2012, Pages 787-809

  Gooding, Matt ^a   Browne, Lorcan P ^a   Quinteiro, Filipa M ^a   Selwood, David L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Carbohydrate; Chemical structure; Drug delivery ADMET; Lipid; Nanotechnology (drug discovery); Nucleic acid; RNAi and antisense techniques

Indexed keywords

AGN 211745; AGN 21745; AHR SMALL INTERFERING RNA; ALN RSV 01; ALN TTR01; ALN VSP02; ANTISENSE OLIGONUCLEOTIDE; ATU 027; BEVASIRANIB; CALAA 1; CARBAMIC ACID DERIVATIVE; CELL PENETRATING PEPTIDE; EBOLA VACCINE; FOMIVERSIN; I5NP; INTERLEUKIN 10 SMALL INTERFERING RNA; LIPID; MIPOMERSIN; MIRAVIRSEN; PF 04523655; PRO 040201; PROTEOSOME SMALL INTERFERING RNA; QPI 1007; SIG12D LODER; SMALL INTERFERING RNA; SMALL MOLECULE TRANSPORT AGENT; SV40 VECTOR; SYL 040012; TD 101; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTISENSE THERAPY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE THERAPY; HEALTH CARE SYSTEM; HUMAN; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RNA INTERFERENCE; SEQUENCE ANALYSIS;

ANIMALS; BIOMIMETIC MATERIALS; CELL MEMBRANE; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; LIPOSOMES; NANOPARTICLES; POLYMERS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84868007709     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12052     Document Type: Review

References (171)

1. Leaman D.W. (2008) Recent progress in oligonucleotide therapeutics: antisense to aptamers. Expert Opin Drug Discov;3:997-1009.
2. Kastelein J.J.P., Wedel M.K., Baker B.F., Su J., Bradley J.D., Yu R.Z. et al. (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation;114:1729-1735.
3. Fire A., Xu S.Q., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature;391:806-811.
4. Love T.M., Moffett H.F., Novina C.D. (2008) Not miR-ly small RNAs: big potential for microRNAs in therapy. J Allergy Clin Immunol;121:309-319.
5. William C.S.C. (2010) MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol;42:1273-1281.
6. Bertrand J.-R., Pottier M., Vekris A., Opolon P., Maksimenko A., Malvy C. (2002) Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun;296:1000-1004.
7. Bennett C.F., Swayze E.E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol;50:259-293.
8. Sontheimer E.J. (2005) Assembly and function of RNA silencing complexes. Nat Rev Mol Cell Biol;6:127-138.
9. Goyal B.R., Patel M.M., Soni M.K., Bhadada S.V. (2009) Therapeutic opportunities of small interfering RNA. Fundam Clin Pharmacol;23:367-386.
10. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature;411:494-498.
11. Chiu Y.-L., Ali A., Chu C.-y., Cao H., Rana T.M. (2004) Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol;11:1165-1175.
12. Meister G., Tuschl T. (2004) Mechanisms of gene silencing by double-stranded RNA. Nature;431:343-349.
13. Wang Y., Sheng G., Juranek S., Tuschl T., Patel D.J. (2008) Structure of the guide-strand-containing argonaute silencing complex. Nature;456:209-213.
14. Tian Y., Simanshu D.K., Ma J.B., Patel D.J. (2011) Structural basis for piRNA 2'-O-methylated 3'-end recognition by Piwi PAZ (Piwi/Argonaute/Zwille) domains. Proc Natl Acad Sci USA;108:903-910.
15. Parker J.S. (2010) How to slice: snapshots of Argonaute in action. Silence;1:3.
16. Jagannath A., Wood M.J. (2009) Localization of double-stranded small interfering RNA to cytoplasmic processing bodies is Ago2 dependent and results in up-regulation of GW182 and Argonaute-2. Mol Biol Cell;20:521-529.
17. Huang L., Mollet S., Souquere S., Le Roy F., Ernoult-Lange M., Pierron G. et al. (2011) Mitochondria associate with P-bodies and modulate microRNA-mediated RNA interference. J Biol Chem;286:24219-24230.
18. Eulalio A., Behm-Ansmant I., Schweizer D., Izaurralde E. (2007) P-body formation is a consequence, not the cause, of RNA-mediated gene silencing. Mol Cell Biol;27:3970-3981.
19. Shim M.S., Kwon Y.J. (2010) Efficient and targeted delivery of siRNA in vivo. FEBS J;277:4814-4827.
20. Guo J., Fisher K.A., Darcy R., Cryan J.F., O'Driscoll C. (2010) Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Mol BioSyst;6:1143-1161.
21. Turchinovich A., Zoidl G., Dermietzel R. (2010) Non-viral siRNA delivery into the mouse retina in vivo. BMC Ophthalmol;10:25.
22. Cho W.G., Albuquerque R.J.C., Kleinman M.E., Tarallo V., Greco A., Nozaki M. et al. (2009) Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci;106:7137-7142.
23. Whitehead K., Langer R., Anderson D. (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov;8:129-138.
24. Barquinero J., Eixarch H., Perez-Melgosa M. (2004) Retroviral vectors: new applications for an old tool. Gene Ther;11:S3-S9.
25. Zhu L., Mahato R.I. (2010) Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin Drug Deliv;7:1209-1226.
26. Eguchi A., Meade B.R., Chang Y.C., Fredrickson C.T., Willert K., Puri N. et al. (2009) Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol;27:567-U110.
27. Omidi Y., Hollins A.J., Benboubetra M., Drayton R., Benter I.F., Akhtar S. (2003) Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J Drug Target;11:311-323.
28. El Andaloussi S., Lehto T., Mager I., Rosenthal-Aizman K., Oprea I.I., Simonson O.E. et al. (2011) Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res;39:3972-3987.
29. Frankel A.D., Pabo C.O. (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell;55:1189-1193.
30. Joliot A., Pernelle C., Deagostini-Bazin H., Prochiantz A. (1991) Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci;88:1864-1868.
31. Derossi D., Joliot A.H., Chassaing G., Prochiantz A. (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem;269:10444-10450.
32. Vivès E., Brodin P., Lebleu B. (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem;272:16010-16017.
33. Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science;285:1569-1572.
34. Morris M.C., Depollier J., Mery J., Heitz F., Divita G. (2001) A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol;19:1173-1176.
35. Fawell S., Seery J., Daikh Y., Moore C., Chen L.L., Pepinsky B. et al. (1994) Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci;91:664-668.
36. Ruan G., Agrawal A., Marcus A.I., Nie S. (2007) Imaging and tracking of tat peptide-conjugated quantum dots in living cells: new insights into nanoparticle uptake, intracellular transport, and vesicle shedding. J Am Chem Soc;129:14759-14766.
37. Abes R., Arzumanov A.A., Moulton H.M., Abes S., Lvanciva G.D., Lversen P.L. et al. (2007) Cell-penetrating-peptide-based delivery of oligonucleotides: an overview. Biochem Soc Trans;35:775-779.
38. Juliano R., Alam M.R., Dixit V., Kang H. (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res;36:4158-4171.
39. Langel U. (2010) Cell-penetrating Peptides. New York: Springer.
40. Wender P.A., Galliher W.C., Goun E.A., Jones L.R., Pillow T.H. (2008) The design of guanidinium-rich transporters and their internalization mechanisms. Adv Drug Deliv Rev;60:452-472.
41. Wender P.A., Cooley C.B., Geihe E.I. (2011) Beyond cell penetrating peptides: designed molecular transporters. Drug Discov Today Technol:e49-e55.
42. Wender P.A., Mitchell D.J., Pattabiraman K., Pelkey E.T., Steinman L., Rothbard J.B. (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA;97:13003-13008.
43. Higashi T., Khalil I.A., Maiti K.K., Lee W.S., Akita H., Harashima H. et al. (2009) Novel lipidated sorbitol-based molecular transporters for non-viral gene delivery. J Control Release;136:140-147.
44. Maiti K.K., Lee W.S., Takeuchi T., Watkins C., Fretz M., Kim D.C. et al. (2007) Guanidine-containing molecular transporters: sorbitol-based transporters show high intracellular selectivity toward mitochondria. Angew Chem;46:5880-5884.
45. Maiti K.K., Jeon O.Y., Lee W.S., Chung S.K. (2007) Design, synthesis, and delivery properties of novel guanidine-containing molecular transporters built on dimeric inositol scaffolds. Chemistry;13:762-775.
46. Biswas G., Jeon O.Y., Lee W.S., Kim D.C., Kim K.T., Lee S. et al. (2008) Novel guanidine-containing molecular transporters based on lactose scaffolds: lipophilicity effect on the intracellular organellar selectivity. Chemistry;14:9161-9168.
47. Pereira M.P., Kelley S.O. (2011) Maximizing the therapeutic window of an antimicrobial drug by imparting mitochondrial sequestration in human cells. J Am Chem Soc;133:3260-3263.
48. Ross M.F., Prime T.A., Abakumova I., James A.M., Porteous C.M., Smith R.A. et al. (2008) Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells. Biochem J;411:633-645.
49. Malouitre S., Dube H., Selwood D., Crompton M. (2010) Mitochondrial targeting of cyclosporin A enables selective inhibition of cyclophilin-D and enhanced cytoprotection after glucose and oxygen deprivation. Biochem J;425:137-148.
50. Kelley S.O., Stewart K.M., Mourtada R. (2011) Development of novel peptides for mitochondrial drug delivery: amino acids featuring delocalized lipophilic cations. Pharm Res;28:2808-2819.
51. Ross M.F., Filipovska A., Smith R.A., Gait M.J., Murphy M.P. (2004) Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers. Biochem J;383:457-468.
52. Okuyama M., Laman H., Kingsbury S.R., Visintin C., Leo E., Eward K.L. et al. (2007) Small-molecule mimics of an [alpha]-helix for efficient transport of proteins into cells. Nat Methods;4:153-159.
53. Jacoby E. (2002) Biphenyls as potential mimetics of protein [alpha]-helix. Bioorg Med Chem Lett;12:891-893.
54. Ho A., Schwarze S.R., Mermelstein S.J., Waksman G., Dowdy S.F. (2001) Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res;61:474-477.
55. Depamphilis M.L. (2011) Spotlight on geminin. Breast Cancer Res;13:109.
56. Okorokov A.L., Orlova E.V., Kingsbury S.R., Bagneris C., Gohlke U., Williams G.H. et al. (2004) Molecular structure of human geminin. Nat Struct Mol Biol;11:1021-1022.
57. Cooley C.B., Trantow B.M., Nederberg F., Kiesewetter M.K., Hedrick J.L., Waymouth R.M. et al. (2009) Oligocarbonate molecular transporters: oligomerization-based syntheses and cell-penetrating studies. J Am Chem Soc;131:16401-16403.
58. Bautista A.D., Craig C.J., Harker E.A., Schepartz A. (2007) Sophistication of foldamer form and function in vitro and in vivo. Curr Opin Chem Biol;11:685-692.
59. Gillies E.R., Deiss F., Staedel C., Schmitter J.M., Huc I. (2007) Development and biological assessment of fully water-soluble helical aromatic amide foldamers. Angew Chem;46:4081-4084.
60. Som A., Xu Y., Scott R.W., Tew G.N. (2012) Anion mediated activation of guanidine rich small molecules. Org Biomol Chem;10:40-42.
61. Kolonko E.M., Kiessling L.L. (2008) A polymeric domain that promotes cellular internalization. J Am Chem Soc;130:5626-5627.
62. Kolonko E.M., Pontrello J.K., Mangold S.L., Kiessling L.L. (2009) General synthetic route to cell-permeable block copolymers via ROMP. J Am Chem Soc;131:7327-7333.
63. Hennig A., Gabriel G.J., Tew G.N., Matile S. (2008) Stimuli-responsive polyguanidino-oxanorbornene membrane transporters as multicomponent sensors in complex matrices. J Am Chem Soc;130:10338-10344.
64. Wender P.A., Kreider E., Pelkey E.T., Rothbard J., Vandeusen C.L. (2005) Dendrimeric molecular transporters: synthesis and evaluation of tunable polyguanidino dendrimers that facilitate cellular uptake. Org Lett;7:4815-4818.
65. Juliano R. (2007) Challenges to macromolecular drug delivery. Biochem Soc Trans;35:41-43.
66. Merkel O.M., Mintzer M.A., Librizzi D., Samsonova O., Dicke T., Sproat B. et al. (2010) Triazine dendrimers as nonviral vectors for in vitro and in vivo RNAi: the effects of peripheral groups and core structure on biological activity. Mol Pharm;7:969-983.
67. Derossi D., Calvet S., Trembleau A., Brunissen A., Chassaing G., Prochiantz A. (1996) Cell Internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem;271:18188-18193.
68. Richard J.P., Melikov K., Vives E., Ramos C., Verbeure B., Gait M.J. et al. (2003) Cell-penetrating peptides - a reevaluation of the mechanism of cellular uptake. J Biol Chem;278:585-590.
69. Jiao C.Y., Delaroche D., Burlina F., Alves I.D., Chassaing G., Sagan S. (2009) Translocation and endocytosis for cell-penetrating peptide internalization. J Biol Chem;284:33957-33965.
70. Guterstam P., Madani F., Hirose H., Takeuchi T., Futaki S., El Andaloussi S. et al. (2009) Elucidating cell-penetrating peptide mechanisms of action for membrane interaction, cellular uptake, and translocation utilizing the hydrophobic counter-anion pyrenebutyrate. Biochim Biophys Acta;1788:2509-2517.
71. Belting M., Wittrup A. (2009) Macromolecular drug delivery: basic principles and therapeutic applications. Mol Biotechnol;43:89-94.
72. Ezzat K., Helmfors H., Tudoran O., Juks C., Lindberg S., Padari K. et al. (2012) Scavenger receptor-mediated uptake of cell-penetrating peptide nanocomplexes with oligonucleotides. FASEB J;26:1172-1180.
73. Iversen T.-G., Skotland T., Sandvig K. (2011) Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nano Today;6:176-185.
74. Lundberg M., Wikstrom S., Johansson M. (2003) Cell surface adherence and endocytosis of protein transduction domains. Mol Ther;8:143-150.
75. Nakase I., Niwa M., Takeuchi T., Sonomura K., Kawabata N., Koike Y. et al. (2004) Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther;10:1011-1022.
76. Nakase I., Tadokoro A., Kawabata N., Takeuchi T., Katoh H., Hiramoto K. et al. (2006) Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry;46:492-501.
77. Simon M.J., Gao S., Kang W.H., Banta S., Morrison B. (2009) TAT-mediated intracellular protein delivery to primary brain cells is dependent on glycosaminoglycan expression. Biotechnol Bioeng;104:10-19.
78. Patel L.N., Zaro J.L., Shen W.C. (2007) Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res;24:1977-1992.
79. Fuchs S.M., Raines R.T. (2004) Pathway for polyarginine entry into mammalian cells. Biochemistry;43:2438-2444.
80. Gerbal-chaloin S., Gondeau C., Aldrian-herrada G., Heitz F., Gauthier-rouvière C., Divita G. (2007) First step of the cell-penetrating peptide mechanism involves Rac1 GTPase-dependent actin-network remodelling. Biol Cell;099:223-238.
81. Couchman J.R. (2003) Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol;4:926-938.
82. Conner S.D., Schmid S.L. (2003) Regulated portals of entry into the cell. Nature;422:37-44.
83. Palte M.J., Raines R.T. (2012) Interaction of nucleic acids with the glycocalyx. J Am Chem Soc;134:6218-6223.
84. Ziegler A. (2008) Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans. Adv Drug Deliv Rev;60:580-597.
85. Ziegler A., Seelig J. (2004) Interaction of the protein transduction domain of HIV-1 TAT with heparan sulfate: binding mechanism and thermodynamic parameters. Biophys J;86:254-263.
86. Ziegler A., Seelig J. (2008) Binding and clustering of glycosaminoglycans: a common property of mono- and multivalent cell-penetrating compounds. Biophys J;94:2142-2149.
87. Gump J.M., June R.K., Dowdy S.F. (2010) Revised role of glycosaminoglycans in TAT protein transduction domain-mediated cellular transduction. J Biol Chem;285:1500-1507.
88. Esbjorner E.K., Lincoln P., Norden B. (2007) Counterion-mediated membrane penetration: cationic cell-penetrating peptides overcome Born energy barrier by ion-pairing with phospholipids. Biochim Biophys Acta;1768:1550-1558.
89. Rothbard J.B., Jessop T.C., Wender P.A. (2005) Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv Drug Deliv Rev;57:495-504.
90. El-Sayed A., Khalil I.A., Kogure K., Futaki S., Harashima H. (2008) Octaarginine- and Octalysine-modified nanoparticles have different modes of endosomal escape. J Biol Chem;283:23450-23461.
91. Sakai N., Matile S. (2003) Anion-mediated transfer of polyarginine across liquid and bilayer membranes. J Am Chem Soc;125:14348-14356.
92. Mishra A., Gordon V.D., Yang L., Coridan R., Wong G.C. (2008) HIV TAT forms pores in membranes by inducing saddle-splay curvature: potential role of bidentate hydrogen bonding. Angew Chem Int Ed;47:2986-2989.
93. Lamazière A., Wolf C., Lambert O., Chassaing G., Trugnan G., Ayala-Sanmartin J. (2008) The homeodomain derived peptide Penetratin induces curvature of fluid membrane domains. PLoS ONE;3:e1938.
94. Yezid H., Konate K., Debaisieux S., Bonhoure A., Beaumelle B. (2009) Mechanism for HIV-1 Tat insertion into the endosome membrane. J Biol Chem;284:22736-22746.
95. Koshkin A.A., Singh S.K., Nielsen P., Rajwanshi V.K., Kumar R., Meldgaard M. et al. (1998) LNA (Locked Nucleic Acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron;54:3607-3630.
96. Elmén J., Thonberg H., Ljungberg K., Frieden M., Westergaard M., Xu Y. et al. (2005) Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res;33:439-447.
97. Mook O.R., Baas F., de Wissel M.B., Fluiter K. (2007) Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther;6:833-843.
98. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M. et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature;432:173-178.
99. Wolfrum C., Shi S., Jayaprakash K.N., Jayaraman M., Wang G., Pandey R.K. et al. (2007) Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol;25:1149-1157.
100. Crombez L., Aldrian-Herrada G., Konate K., Nguyen Q.N., McMaster G.K., Brasseur R. et al. (2009) A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther;17:95-103.
101. Gooding M., Tudzarova S., Worthington R.J., Kingsbury S.R., Rebstock A.-S., Dube H. et al. (2011) Exploring the interaction between siRNA and the SMoC biomolecule transporters: implications for small molecule mediated delivery of siRNA. Chem Biol Drug Des;79:9-21.
102. Jarvis A., Allerston C.K., Jia H., Herzog B., Garza-Garcia A., Winfield N. et al. (2010) Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem;53:2215-2226.
103. Rebstock A.S., Visintin C., Leo E., Garcia Posada C., Kingsbury S.R., Williams G.H. et al. (2008) Modular assembly using sequential palladium coupling gives easy access to the SMoC class of cellular transporters. ChemBioChem;9:1787-1796.
104. Veldhoen S., Laufer S.D., Trampe A., Restle T. (2006) Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res;34:6561-6573.
105. Soenen S.J.H., Brisson A.R., De Cuyper M. (2009) Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model. Biomaterials;30:3691-3701.
106. Jia H., Bagherzadeh A., Hartzoulakis B., Jarvis A., Lohr M., Shaikh S. et al. (2006) Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor exon 8 for NP-1 binding and role of NP-1 in KDR signaling. J Biol Chem;281:13493-13502.
107. Muratovska A., Eccles M.R. (2004) Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett;558:63-68.
108. Meade B.R., Dowdy S.F. (2007) Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev;59:134-140.
109. Davidson T.J., Harel S., Arboleda V.A., Prunell G.F., Shelanski M.L., Greene L.A. et al. (2004) Highly efficient small interfering RNA delivery to primary mammalian neurons induces microRNA-like effects before mRNA degradation. J Neurosci;24:10040-10046.
110. Moschos S.A., Jones S.W., Perry M.M., Williams A.E., Erjefalt J.S., Turner J.J. et al. (2007) Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem;18:1450-1459.
111. Simeoni F., Morris M.C., Heitz F., Divita G. (2003) Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res;31:2717-2724.
112. Chan A.W., Laskowski R.A., Selwood D.L. (2010) Chemical fragments that hydrogen bond to Asp, Glu, Arg, and His side chains in protein binding sites. J Med Chem;53:3086-3094.
113. Lundberg P., El Andaloussi S., Sutlu T., Johansson H., Langel U. (2007) Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J;21:2664-2671.
114. Magzoub M., Pramanik A., Graslund A. (2005) Modeling the endosomal escape of cell-penetrating peptides: transmembrane pH gradient driven translocation across phospholipid bilayers. Biochemistry;44:14890-14897.
115. Unnamalai N., Kang B.G., Lee W.S. (2004) Cationic oligopeptide-mediated delivery of dsRNA for post-transcriptional gene silencing in plant cells. FEBS Lett;566:307-310.
116. Kim S.W., Kim N.Y., Choi Y.B., Park S.H., Yang J.M., Shin S. (2010) RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. J Controlled Release;143:335-343.
117. Konate K., Crombez L., Deshayes S., Decaffmeyer M., Thomas A., Brasseur R. et al. (2010) Insight into the cellular uptake mechanism of a secondary amphipathic cell-penetrating peptide for siRNA delivery. Biochemistry;49:3393-3402.
118. Gooding M., Tudzarova S., Worthington R.J., Kingsbury S.R., Rebstock A.S., Dube H. et al. (2012) Exploring the interaction between siRNA and the SMoC biomolecule transporters: implications for small molecule-mediated delivery of siRNA. Chem Biol Drug Des;79:9-21.
119. Arthanari Y., Pluen A., Rajendran R., Aojula H., Demonacos C. (2010) Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in chronic myeloid leukemia cells. J Controlled Release;145:272-280.
120. Ishihara T., Goto M., Kodera K., Kanazawa H., Murakami Y., Mizushima Y. et al. (2009) Intracellular delivery of siRNA by cell-penetrating peptides modified with cationic oligopeptides. Drug Delivery;16:153-159.
121. Endoh T., Sisido M., Ohtsuki T. (2008) Cellular siRNA delivery mediated by a cell-permeant RNA-binding protein and photoinduced RNA interference. Bioconjug Chem;19:1017-1024.
122. Lensink M.F., Christiaens B., Vandekerckhove J., Prochiantz A., Rosseneu M. (2005) Penetratin-membrane association: W48/R52/W56 shield the peptide from the aqueous phase. Biophys J;88:939-952.
123. Waite C.L., Sparks S.M., Uhrich K.E., Roth C.M. (2009) Acetylation of PAMAM dendrimers for cellular delivery of siRNA. BMC Biotechnol;9:38.
124. Waite C.L., Roth C.M. (2011) Binding and transport of PAMAM-RGD in a tumor spheroid model: the effect of RGD targeting ligand density. Biotechnol Bioeng;108:2999-3008.
125. Merkel O.M., Zheng M., Mintzer M.A., Pavan G.M., Librizzi D., Maly M. et al. (2011) Molecular modeling and in vivo imaging can identify successful flexible triazine dendrimer-based siRNA delivery systems. J Control Release;153:23-33.
126. Rao N.M. (2010) Cationic lipid-mediated nucleic acid delivery: beyond being cationic. Chem Phys Lipids;163:245-252.
127. Li W., Szoka F.C. (2007) Lipid-based nanoparticles for nucleic acid delivery. Pharm Res;24:438-449.
128. Rozema D.B., Lewis D.L., Wakefield D.H., Wong S.C., Klein J.J., Roesch P.L. et al. (2007) Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci;104:12982-12987.
129. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M. et al. (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci;84:7413-7417.
130. Malone R.W., Felgner P.L., Verma I.M. (1989) Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci;86:6077-6081.
131. Behr J.P., Demeneix B., Loeffler J.P., Perez-Mutul J. (1989) Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc Natl Acad Sci;86:6982-6986.
132. Gao X., Huang L. (1991) A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun;179:280-285.
133. Rose J.K., Buonocore L., Whitt M.A. (1991) A new cationic liposome reagent mediating nearly quantitative transfection of animal cells. Biotechniques;10:520-525.
134. San H., Yang Z.Y., Pompili V.J., Jaffe M.L., Plautz G.E., Xu L. et al. (1993) Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther;4:781-788.
135. Dalby B., Cates S., Harris A., Ohki E.C., Tilkins M.L., Price P.J. et al. (2004) Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods;33:95-103.
136. Filion M.C., Phillips N.C. (1997) Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta;1329:345-356.
137. Hunt M.A., Currie M.J., Robinson B.A., Dachs G.U. (2010) Optimizing transfection of primary human umbilical vein endothelial cells using commercially available chemical transfection reagents. J Biomol Tech;21:66-72.
138. Yamazaki Y., Nango M., Matsuura M., Hasegawa Y., Hasegawa M., Oku N. (2000) Polycation liposomes, a novel nonviral gene transfer system, constructed from cetylated polyethylenimine. Gene Ther;7:1148-1155.
139. Zhong Y.Q., Wei J., Fu Y.R., Shao J., Liang Y.W., Lin Y.H. et al. (2008) Toxicity of cationic liposome Lipofectamine 2000 in human pancreatic cancer Capan-2 cells. Nan Fang Yi Ke Da Xue Xue Bao;28:1981-1984.
140. Kedmi R., Ben-Arie N., Peer D. (2010) The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials;31:6867-6875.
141. Farhood H., Serbina N., Huang L. (1995) The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta;1235:289-295.
142. Xu L., Anchordoquy T.J. (2008) Cholesterol domains in cationic lipid/DNA complexes improve transfection. Biochim Biophys Acta;1778:2177-2181.
143. Siegel D.P., Epand R.M. (1997) The mechanism of lamellar-to-inverted hexagonal phase transitions in phosphatidylethanolamine: implications for membrane fusion mechanisms. Biophys J;73:3089-3111.
144. Zhang J., Fan H., Levorse D.A., Crocker L.S. (2011) Interaction of cholesterol-conjugated ionizable amino lipids with biomembranes: lipid polymorphism, structure-activity relationship, and implications for siRNA delivery. Langmuir;27:9473-9483.
145. Simberg D., Weisman S., Talmon Y., Faerman A., Shoshani T., Barenholz Y. (2003) The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection. J Biol Chem;278:39858-39865.
146. Hirsch-Lerner D., Zhang M., Eliyahu H., Ferrari M.E., Wheeler C.J., Barenholz Y. (2005) Effect of "helper lipid" on lipoplex electrostatics. Biochim Biophys Acta;1714:71-84.
147. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W. et al. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol;23:1002-1007.
148. Zimmermann T.S., Lee A.C.H., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N. et al. (2006) RNAi-mediated gene silencing in non-human primates. Nature;441:111-114.
149. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K. et al. (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol;28:172-176.
150. Mével M., Kamaly N., Carmona S., Oliver M.H., Jorgensen M.R., Crowther C. et al. (2010) DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Controlled Release;143:222-232.
151. Klein E., Leborgne C., Ciobanu M., Klein J., Frisch B., Pons F. et al. (2010) Nucleic acid transfer with hemifluorinated polycationic lipids. Biomaterials;31:4781-4788.
152. Jayaraman M., Ansell S.M., Mui B.L., Tam Y.K., Chen J., Du X. et al. (2011) Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed;51(34):8529-8533.
153. Geisbert T.W., Lee A.C.H., Robbins M., Geisbert J.B., Honko A.N., Sood V. et al. (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet;375:1896-1905.
154. Akinc A., Querbes W., De S., Qin J., Frank-Kamenetsky M., Jayaprakash K.N. et al. (2010) Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther;18:1357-1364.
155. Kuwahara H., Nishina K., Yoshida K., Nishina T., Yamamoto M., Saito Y. et al. (2011) Efficient in vivo delivery of siRNA into brain capillary endothelial cells along with endogenous lipoprotein. Mol Ther;19(12):2213-2221.
156. Uno Y., Piao W., Miyata K., Nishina K., Mizusawa H., Yokota T. (2011) High-density lipoprotein facilitates in vivo delivery of alpha-tocopherol-conjugated short-interfering RNA to the brain. Hum Gene Ther;22:711-719.
157. Nimesh S. (2012) Polyethylenimine as a promising vector for targeted siRNA delivery. Curr Clin Pharmacol;7:121-130.
158. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., Aigner A. (2004) RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther;12:461-466.
159. Sonawane N.D., Szoka F.C., Verkman A.S. (2003) Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem;278:44826-44831.
160. Thomas M., Lu J.J., Ge Q., Zhang C., Chen J., Klibanov A.M. (2005) Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc Natl Acad Sci;102:5679-5684.
161. Fischer D., Li Y., Ahlemeyer B., Krieglstein J., Kissel T. (2003) In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials;24:1121-1131.
162. Méndez-Ardoy A., Urbiola K., Aranda C., Ortiz-Mellet C., García-Fernández J.M., Tros de Ilarduya C. (2011) Polycationic amphiphilic cyclodextrin-based nanoparticles for therapeutic gene delivery. Nanomedicine (Lond);6:1697-1707.
163. Kulkarni A., DeFrees K., Hyun S.-H., Thompson D.H. (2012) Pendant polymer: amino-β-cyclodextrin: siRNA guest: host nanoparticles as efficient vectors for gene silencing. J Am Chem Soc;134:7596-7599.
164. Zuckerman J.E., Choi C.H.J., Han H., Davis M.E. (2012) Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci;109:3137-3142.
165. Giezen T.J., Mantel-Teeuwisse A.K., Straus S.M.J.M., Schellekens H., Leufkens H.G.M., Egberts A.C.G. (2008) Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA;300:1887-1896.
166. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov;6:443-453.
167. Jain K., Kesharwani P., Gupta U., Jain N.K. (2010) Dendrimer toxicity: let's meet the challenge. Int J Pharm;394:122-142.
168. Leachman S.A., Hickerson R.P., Schwartz M.E., Bullough E.E., Hutcherson S.L., Boucher K.M. et al. (2009) First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther;18:442-446.
169. Clutterbuck L.A., Posada C.G., Visintin C., Riddall D.R., Lancaster B., Gane P.J. et al. (2009) Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem;52:2694-2707.
170. Kim W.J., Christensen L.V., Jo S., Yockman J.W., Jeong J.H., Kim Y.-H. et al. (2006) Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther;14:343-350.
171. Crombez L., Morris M.C., Dufort S., Aldrian-Herrada G., Nguyen Q., McMaster G. et al. (2009) Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res;37:4559-4569.